Concepedia

Author

Matthias Klinger

Amgen (Germany)ORCID

Also Known As

M Klinger, M. Klinger, Matthias Klinger

37

Publications

4.5K

Citations

18

H-Index

31

Concepts

All Affiliations

Amgen (Germany)Amgen (United States)Goethe University FrankfurtUniversity Hospital Ulm3D-Micromac (Germany)
MK

About

Matthias Klinger is an author at Amgen (Germany) specializing in medicine, tumor immunity, and radiation oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

4

4

1.2K

2

Immunology

3

3

1.1K

3

Health Sciences

1

1

15

4

Cell Biology

1

1

11

5

Cellular Physiology

1

1

11

Matthias Klinger

×

16

Publications

4K

Citations

15

H-Index

YearCitations

Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody

Ralf C. Bargou, Eugen Leo, Gerhard Zugmaier,

Science

2008

1.1K

Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival

Max S. Topp, Peter Kufer, Nicola Gökbuget,

Journal of Clinical Oncology

2011

902

Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL

Max S. Topp, Nicola Gökbuget, Gerhard Zugmaier,

Blood

2012

466

Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell–engaging CD19/CD3-bispecific BiTE antibody blinatumomab

Matthias Klinger, Christian Brandl, Gerhard Zugmaier,

Blood

2012

459

Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study

Maria-Elisabeth Goebeler, Stefan Knop, Andreas Viardot,

Journal of Clinical Oncology

2016

414

Strictly Target Cell-dependent Activation of T Cells by Bispecific Single-chain Antibody Constructs of the BiTE Class

Klaus Brischwein, Larissa Parr, Stefan Pflanz,

Journal of Immunotherapy

2007

188

Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment

Gerhard Zugmaier, Nicola Gökbuget, Matthias Klinger,

Blood

2015

157

Adhesion of T Cells to Endothelial Cells Facilitates Blinatumomab-Associated Neurologic Adverse Events

Matthias Klinger, Gerhard Zugmaier, Virginie Nägele,

Cancer Research

2019

77

Targeting Solid Tumors with Bispecific T Cell Engager Immune Therapy

Tara Arvedson, Julie M. Bailis, Carolyn D. Britten,

Annual Review of Cancer Biology

2021

72

Changes in clinical laboratory parameters and pharmacodynamic markers in response to blinatumomab treatment of patients with relapsed/refractory ALL

Virginie Nägele, Andrea Kratzer, Gerhard Zugmaier,

Experimental Hematology and Oncology

2017

71

Page 1